# Thyroid GuidePx®

The first genomic classifier for papillary thyroid cancer.

For years, thyroid surgeons have relied on clinical risk stratification to make treatment decisions on papillary thyroid cancer. Clinical risk stratification is <60% accurate, and does not account for tumor biology. Thyroid GuidePx® is >80% accurate, *because* it is informed by tumor biology.

Accurate.

ATA System
High- and intermediate risk vs. low risk

Molecular Subtype +
Early/Advanced

Outperforms the ATA clinical risk stratification system.
More than 80% accuracy.
Identifies high risk PTCs with high sensitivity.

Identifies low risk PTC with >96% specificity.

<3% recurrence rate

Progression-free survival

Log rank p = 3.5×10^{-8}

Months

Confidently identify low risk patients.
Avoid overtreatment in appropriate candidates for conservative management.

## Simple.

1 The pathology specimen is sent to our lab.

2 We perform next generation sequencing, measuring the expression of 82 prognostic genes.

3 Type 1 Type 2 Type 3

Our proprietary algorithm, built using advanced machine learning and backed by clinical research, identifies the molecular subtype.

4 You get a test report describing biological features and recurrence risks.

Cost Effective.

Reduces the % of patients that require a completion thyroidectomy, increasing quality adjusted life years (QALYs) per patient. Cost savings compared to standard of care.

Questions? admin@qualisuredx.com

To Order: https://qualisuredx.com/how-to-order/